BioSpace News Archive

Hangzhou Tigermed Consulting Co., Ltd., a leading provider of clinical research solutions across full lifecycle of global biopharmaceutical and medical device products, announced its interim results for the first half of 2023, ended June 30, 2023.

Medtronic plc (NYSE:MDT), a global leader in healthcare technology, has received CE (Conformité Européenne) Mark approval for its Inceptiv™ closed-loop rechargeable spinal cord stimulator (SCS).

Henlius announced its 2023 interim results. In the first half of 2023, Henlius reported a boost in operating profits of RMB240.0 million and revenues of RMB2.5005 billion, up by 93.9% YoY, driven by growth in core oncology products.

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) today announced that Chirag Patel, Co-Chief Executive Officer and President, and Tasos Konidaris, Chief Financial Officer, will participate at the 2023 Wells Fargo Healthcare Conference on September 7, 2023 in Boston.

DermTech, Inc., a leader in precision dermatology enabled by a non-invasive skin genomics technology, announced the grant to six new employees of restricted stock units representing the contingent right to receive up to an aggregate of 24,720 shares of the Company’s common stock under its 2022 Inducement Equity Incentive Plan, as amended, or the 2022 Inducement Plan.

Biocept, Inc. (Nasdaq: BIOC) management will hold a conference call on August 30, 2023, beginning at 4:00 p.m. Eastern time (1:00 p.m. Pacific time) to provide a business update and to answer questions.

Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today reported financial results for the second quarter ended June 30, 2023 and reviewed recent business highlights.

Aetion®, the global leader in real-world evidence (RWE) technology and analytics, is pleased to announce that ‘A Screening Tool to Evaluate whether Using Real-world Data to Support an Effectiveness Claim in an FDA Application has Regulatory Feasibility (SURF)’ was published today in Clinical Pharmacology & Therapeutics.

SkinCure Oncology announced its availability in Kentucky at an event at the Louisville office of Dr. Denise T. Dickinson M.D. It is the first medical practice in the state to offer this GentleCure™ treatment experience.

SUSMED, Inc. (TOKYO:4263) announced that it obtained regulatory approval from the Ministry of Health, Labour and Welfare (the ”MHLW”) of SUSMED Med CBT-i® App for Insomnia (the ”product”).